Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566540 · ClinicalTrials.gov registry record · Phase 2
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00566540 is a Phase 2 study that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 11 participants.
The verdict
NCT00566540, a Phase 2 study, was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving cisplatin and paclitaxel together with radiation therapy and surgery works in treating patients with advanced cancer of the oral cavity, oropharynx, or hypopharynx that can be removed by surgery.
Interventions
- DRUG Cisplatin
- DRUG Paclitaxel
- RADIATION Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation
- PROCEDURE Triple endoscopy and biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-12-11 |
| Est. Completion | 2010-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566540
The ClinicalTrials.gov registry entry for NCT00566540 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00566540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566540 about?
NCT00566540 is a clinical study titled "Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together wi...
What is the current status of trial NCT00566540?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2007-12-11. Estimated completion is 2010-02-25.
What interventions are being tested in trial NCT00566540?
The interventions under investigation include: Cisplatin (DRUG), Paclitaxel (DRUG), Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation (RADIATION), Triple endoscopy and biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00566540?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.